HRP950499B1 - Compositions and methods for treating mast-cell inflammatory condition - Google Patents

Compositions and methods for treating mast-cell inflammatory condition

Info

Publication number
HRP950499B1
HRP950499B1 HR950499A HRP950499A HRP950499B1 HR P950499 B1 HRP950499 B1 HR P950499B1 HR 950499 A HR950499 A HR 950499A HR P950499 A HRP950499 A HR P950499A HR P950499 B1 HRP950499 B1 HR P950499B1
Authority
HR
Croatia
Prior art keywords
compositions
methods
inflammatory condition
cell inflammatory
treating mast
Prior art date
Application number
HR950499A
Other languages
English (en)
Inventor
Ken D Rice
Jeffrey M Dener
Anthony R Gangloff
Elaine Y Kuo
Original Assignee
Axys Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharmaceutical filed Critical Axys Pharmaceutical
Publication of HRP950499A2 publication Critical patent/HRP950499A2/hr
Publication of HRP950499B1 publication Critical patent/HRP950499B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HR950499A 1994-09-23 1995-09-22 Compositions and methods for treating mast-cell inflammatory condition HRP950499B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31226994A 1994-09-23 1994-09-23

Publications (2)

Publication Number Publication Date
HRP950499A2 HRP950499A2 (en) 1997-08-31
HRP950499B1 true HRP950499B1 (en) 2003-04-30

Family

ID=23210670

Family Applications (1)

Application Number Title Priority Date Filing Date
HR950499A HRP950499B1 (en) 1994-09-23 1995-09-22 Compositions and methods for treating mast-cell inflammatory condition

Country Status (25)

Country Link
US (2) US6022969A (fr)
EP (1) EP0782571A1 (fr)
JP (1) JPH10506390A (fr)
KR (1) KR970706267A (fr)
CN (1) CN1160398A (fr)
AU (1) AU694275B2 (fr)
CA (1) CA2200561A1 (fr)
CZ (1) CZ87097A3 (fr)
EE (1) EE03525B1 (fr)
FI (1) FI971171A (fr)
HR (1) HRP950499B1 (fr)
HU (1) HUT77770A (fr)
IL (1) IL115405A (fr)
LT (1) LT4234B (fr)
LV (1) LV11865B (fr)
MX (1) MX9702125A (fr)
NO (1) NO309605B1 (fr)
NZ (1) NZ294392A (fr)
PL (1) PL183552B1 (fr)
RU (1) RU2159229C2 (fr)
SI (1) SI9520101A (fr)
SK (1) SK37997A3 (fr)
TW (1) TW442478B (fr)
WO (1) WO1996009297A1 (fr)
ZA (1) ZA958028B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL331465A1 (en) * 1996-07-30 1999-07-19 Axys Pharmaceuticals Novel compounds and agents for treating diseases associated with triptase activity
WO1998024886A1 (fr) * 1996-12-04 1998-06-11 Brigham And Women's Hospital, Inc. Protease issue de mastocytes clivant le fibrogene
US5955431A (en) * 1997-02-05 1999-09-21 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
AU8997498A (en) * 1997-09-05 1999-03-29 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitor
US6221914B1 (en) * 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
EP1030844A1 (fr) * 1997-11-10 2000-08-30 Array Biopharma Inc. Composes inhibant l'activite de la tryptase
EP1060171A2 (fr) * 1998-02-06 2000-12-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs de la tryptase
WO1999040083A2 (fr) * 1998-02-06 1999-08-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs de la tryptase
WO2000014097A2 (fr) * 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouvelles pyranoses
US6362216B1 (en) 1998-10-27 2002-03-26 Array Biopharma Inc. Compounds which inhibit tryptase activity
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
ES2230155T3 (es) * 1999-08-10 2005-05-01 Altana Pharma Ag Derivados de diazocin-diona y su uso como inhibidores de triptasa.
US6960588B1 (en) 1999-09-14 2005-11-01 Altana Pharma Ag Tryptase inhibitors
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
WO2001036386A1 (fr) * 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Traitement du diabete contenant un derive de dipiperazine
JP2003518109A (ja) * 1999-12-20 2003-06-03 アルタナ ファルマ アクチエンゲゼルシャフト トリプターゼ阻害剤
DE60011300T2 (de) 1999-12-20 2005-08-04 Altana Pharma Ag Inhibitoren der tryptase
WO2001052883A1 (fr) * 2000-01-20 2001-07-26 Amgen Inc. Inhibiteurs du recepteur-2 active par une protease (par-2) utilises comme nouveaux agents therapeutiques contre l'asthme
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
PT1358182E (pt) * 2001-01-31 2004-12-31 Altana Pharma Ag Derivados de diazocinas e sua utilizacao como inibidores de triptase
DE60220504T2 (de) 2001-02-21 2008-02-14 Nycomed Gmbh Tryptasehemmer
AU2002253035B8 (en) 2001-02-21 2008-02-21 Altana Pharma Ag Tryptase inhibitors
EP1370518A2 (fr) * 2001-03-15 2003-12-17 ALTANA Pharma AG Inhibiteurs de la tryptase
WO2002074732A2 (fr) * 2001-03-15 2002-09-26 Altana Pharma Ag Inhibiteurs de la tryptase
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
JP2005508871A (ja) 2001-06-19 2005-04-07 アルタナ　ファルマ　アクチエンゲゼルシャフト トリプターゼインヒビター
CA2469607A1 (fr) * 2001-12-13 2003-06-19 Kowa Company, Ltd. Composition pharmaceutique destinee a la prevention ou au traitement de l'hypersensibilite retardee
EP1483241A4 (fr) 2002-03-08 2006-12-13 Bristol Myers Squibb Co Derives cycliques servant de modulateurs de l'activite du recepteur de la chimiokine
TW200524849A (en) * 2003-07-02 2005-08-01 Hoffmann La Roche Hydroxyalkylamide derivatives
US20050255154A1 (en) * 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
TW200815351A (en) * 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
TWI414527B (zh) * 2010-10-06 2013-11-11 Ind Tech Res Inst 異山梨糖醇衍生物及包含該衍生物之液晶顯示器
CN102453037B (zh) * 2010-10-25 2014-06-25 财团法人工业技术研究院 异山梨糖醇衍生物及包含该衍生物的液晶显示器

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4746737A (en) * 1985-07-26 1988-05-24 Kowa Co., Ltd. Phenyl guanidinobenzoate derivatives which have protease inhibitory activity
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
PL176941B1 (pl) * 1993-03-12 1999-08-31 Axys Pharmaceuticals Nowe peptydy i środek farmaceutyczny do leczenia immunologicznych stanów zapalnych
DE69514798D1 (de) * 1994-06-01 2000-03-02 Axys Pharm Inc Zusammensetzungen und verfahren zur behandlung von durch mast-zellen verursachten krankheiten

Also Published As

Publication number Publication date
US6211228B1 (en) 2001-04-03
JPH10506390A (ja) 1998-06-23
TW442478B (en) 2001-06-23
PL183552B1 (pl) 2002-06-28
WO1996009297A1 (fr) 1996-03-28
US6022969A (en) 2000-02-08
HUT77770A (hu) 1998-08-28
ZA958028B (en) 1996-04-18
SI9520101A (en) 1997-12-31
CA2200561A1 (fr) 1996-03-28
NO309605B1 (no) 2001-02-26
PL319587A1 (en) 1997-08-18
EE03525B1 (et) 2001-10-15
NO971305D0 (no) 1997-03-20
NO971305L (no) 1997-05-06
EP0782571A1 (fr) 1997-07-09
RU2159229C2 (ru) 2000-11-20
SK37997A3 (en) 1998-12-02
FI971171A0 (fi) 1997-03-20
FI971171A (fi) 1997-03-20
AU3718095A (en) 1996-04-09
KR970706267A (ko) 1997-11-03
HRP950499A2 (en) 1997-08-31
NZ294392A (en) 1999-05-28
EE9700089A (et) 1997-10-15
MX9702125A (es) 1998-04-30
LV11865B (en) 1998-01-20
LT97065A (en) 1997-08-25
IL115405A (en) 2002-07-25
LV11865A (lv) 1997-10-20
AU694275B2 (en) 1998-07-16
IL115405A0 (en) 1995-12-31
CZ87097A3 (en) 1997-11-12
CN1160398A (zh) 1997-09-24
LT4234B (en) 1997-10-27

Similar Documents

Publication Publication Date Title
HRP950499B1 (en) Compositions and methods for treating mast-cell inflammatory condition
GR3036364T3 (en) Compositions and methods for treating or preventing inflammatory diseases
IL138430A0 (en) Methods and compositions for treating and preventing mucositis
HUP0001454A3 (en) Compositions and methods for treating plants with exogenous chemicals
IL112921A0 (en) Methods and compositions for inhibiting cell proliferative disorders
AU2113295A (en) Novel compositions and methods for water treatment
PL327659A1 (en) Disinfecting compositions and surface disinfecting methods
HUP9900960A3 (en) Disinfecting compositions and method for disinfecting surfaces
AU9214398A (en) Compositions and methods for treating water
HK1031174A1 (en) Compositions and methods for treating diabetes
IL129272A0 (en) Method and composition for treating skin damage
PL336349A1 (en) Compositions for and methods for treating and diagnosing the mastocarcinoma
ZA981600B (en) Methods and compositions for treating stickies
ZA95701B (en) Rivets-nails and methods for their implementation
ZA954984B (en) Compositions and methods for the treatment of tumors
GB2319529B (en) Rinsing method and composition
GB9624501D0 (en) Insecticial compositions and method
IL111554A0 (en) Methods and compositions for hair treatment
EP1064295A4 (fr) PROCEDES ET COMPOSITIONS POUR DIAGNOSTIQUER ET TRAITER LES TROUBLES LIES AU CHROMOSOME-18p
EP0835092A4 (fr) Composition et traitement pour la lutte contre la calvitie
GB2318356B (en) Composition and method
GB9508546D0 (en) Method and composition
GB9414888D0 (en) Method and composition
GB9419087D0 (en) Method and composition
IL138654A0 (en) Methods and materials for treating inflammatory diseases

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: AXYS PHARMACEUTICAL, INC., US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20020922

Year of fee payment: 8

B1PR Patent granted
PBON Lapse due to non-payment of renewal fee

Effective date: 20030923